Novartis/P&G Enablex Deal Offers OTC Switch Option
This article was originally published in The Tan Sheet
Executive Summary
Procter & Gamble is broadening its long-term Rx-to-OTC switch prospects with a co-promotion deal for Novartis' Enablex (darifenacin) extended-release tablets in the U.S
You may also be interested in...
P&G Pharma Sale Could Bring $1 Billion To Feed Consumer Business
A sale of Procter & Gamble's pharma business could fetch about $1 billion, according to an estimate by one analyst. That represents cash P&G could reinvest in its core business areas, beauty and consumer health care, at a time when the recession is impacting growth and the credit crisis is forcing some retailers to cut inventories to conserve cash
Overactive Bladder Category Switch Prospects Questioned By Indevus
Self-selection problems will likely complicate potential Rx-to-OTC switches in the overactive bladder (OAB) category, Indevus Pharmaceuticals execs maintained during an Aug. 9 third quarter earnings call
Novartis Purchase Of Bristol OTCs Has Excedrin Written All Over It
Novartis will enter the U.S. over-the-counter analgesics market with Excedrin as part of the purchase of Bristol-Myers Squibb's OTC portfolio